Patents Assigned to Novo Nordisk, Inc.
  • Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression
    Patent number: 11952574
    Abstract: Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: April 9, 2024
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Anna Linda Blois, Christina Marie Priest, Jihye Park, Henryk Dudek
  • ApoC-II mimetic peptides
    Patent number: 11827690
    Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 28, 2023
    Assignees: Novo Nordisk Inc., United State of America, As Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska
  • Substituted piperidines
    Patent number: 7064135
    Abstract: A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: June 20, 2006
    Assignee: Novo Nordisk Inc.
    Inventor: Florencio Zaragoza Dörwald
  • Glucagon antagonists/inverse agonists
    Patent number: 6953812
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: October 11, 2005
    Assignee: Novo Nordisk, Inc.
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau